Iodixanol
Urothelial Cancer
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
40 Active assets in the Urothelial Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University | Phase 3 | BB |
Axitinib Pfizer | Phase 3 | B |
Pemigatinib Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | B |
Lorlatanib Pfizer | Phase 3 | B |
Cmp 001 Pfizer | Phase 3 | B |
View all 48 →
Same molecule, other indications
Iodixanol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →